

Interests Register

Lung cancer Advisory Committee

Publication Date: 21/01/2019

| Name | Role with NICE | Type of interest | Description of interest | Relevant dates | | | Comments |
|--|--|---------------------------------|--|----------------|-------------------|-----------------|---|
| | | | | Interest arose | Interest declared | Interest ceased | |
| Gary McVeigh | Committee Chair | None | N/A | N/A | N/A | N/A | No action |
| Douglas West From February 2018 Vice-chair from April 2018 | Committee Vice-Chair Thoracic Surgeon | Direct financial (non-specific) | Fees, and travel expenses received from Johnson and Johnson for acting as faculty on a number of sessions for spinal surgeons (ongoing). | Mar 2014 | Dec 2017 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Douglas West From February 2018 Vice-chair from April 2018 | Committee Vice-Chair Thoracic Surgeon | Direct financial (non-specific) | Fees, and travel/accommodation expenses received from Medtronic, for teaching surgical teams how to perform thoracoscopic (VATS) lobectomy operations. | Apr 2017 | Dec 2017 | Apr 2018 | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |

| | | | | | | |
|---|---|--|---|-----------------|-----------------|---|
| <p>Douglas West</p> <p>From February 2018</p> <p>Vice-chair from April 2018</p> | <p>Committee Vice-Chair</p> <p>Thoracic Surgeon</p> | <p>Direct Financial (non-specific)</p> | <p>Fee received from Astra Zeneca. For talks on stage 3 lung cancer, Clinical Expert Group on Immunotherapy for non-small lung cancer</p> | <p>Nov 2017</p> | <p>Dec 2017</p> | <p>No action other than the process of open declaration.</p> <p>Not specific to any topic covered in the scope of the guideline.</p> |
| <p>Douglas West</p> <p>From February 2018</p> <p>Vice-chair from April 2018</p> | <p>Committee Vice-Chair</p> <p>Thoracic Surgeon</p> | <p>Direct non-financial (non-specific)</p> | <p>Part of a panel for Public Health England to support the writing of a report; Perspectives in Lung Cancer Care (organisation of lung cancer services and identifying areas of best practice in Europe that could be applied to the NHS.). Bristol Myers Squibb will pay travel expenses for the 3 meetings</p> | <p>Apr 2018</p> | <p>Apr 2018</p> | <p>No action other than the process of open declaration.</p> <p>Will not focus on specific treatments or drugs covered in the lung cancer guideline update.</p> |
| <p>Shahzeena Aslam</p> | <p>Committee member</p> <p>Clinical Oncologist</p> | <p>Direct financial</p> | <p>Attended British thoracic oncology group conference in Dublin from 24th -26th January 2018. Pfizer have agreed to pay conference fee</p> | <p>Jan 2018</p> | <p>Feb 2018</p> | <p>No action other than the process of open declaration – non-commercial activity.</p> |

| | | | | | | | |
|-----------------|---|------------------------------------|--|----------|----------|--|---|
| Shahzeena Aslam | Committee member Clinical Oncologist | Direct financial (non-specific) | Attended Prostate cancer summit in London, 23rd and 24th Feb 2018 Sponsored by Janssen for travel, accommodation and conference fee. | Feb 2018 | Mar 2018 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Shahzeena Aslam | Committee member Clinical Oncologist | Direct non-financial | Attended a meeting sponsored by BMS in Cambridge exploring clinical cases of lung cancer treated with nivolumab | Mar 2018 | Apr 2018 | | No action other than the process of open declaration |
| Shahzeena Aslam | Committee member Clinical Oncologist | Direct non-financial | Attended a British Thoracic Oncology Group neuroendocrine/small cell lung cancer essential update meeting 18/04/18. Free event. | Apr 2018 | May 2018 | | No action other than the process of open declaration |
| Shahzeena Aslam | Committee member Clinical Oncologist | Direct non-financial | Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and | Jun 2018 | Jun 2018 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|---------------|--|----------------------------------|---|----------|-----------|----------|---|
| | | | accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home. | | | | |
| Elaine Borg | Committee member Pathologist | Direct financial | Honorarium received for lecture at EBUS masterclass. Event hosted by UCLH and sponsored by AstraZeneca | Oct 2017 | Dec 2017 | Oct 2018 | Related to RQ1.2 & RQ1.2 (GComm2, 4.12.17) declaration not made until after the committee meeting. Exclude from any future recommendation making for RQ1.2 & RQ1.2 |
| Elaine Borg | Committee member Pathologist | Direct financial | Honorarium received for lecture at EBUS masterclass June 2018 | Jun 2018 | May 18 | | Related to RQ1.2 & RQ1.2 Exclude from any future recommendation making for RQ1.2 & RQ1.2 |
| Lynn Campbell | Committee member Medical Oncologist | Direct financial (non- specific) | Payment from Pfizer for delivering a presentation: 'Presentation of first-line Crizotinib data'. | Feb 2017 | July 2017 | Feb 2018 | No action other than the process of open declaration |

| | | | | | | | |
|---------------|--|-------------------------------------|--|----------|----------|--|--|
| | | | | | | | Not specific to any topic covered in the scope of the guideline. Crizotinib is one of the cancer TA drugs which is in the chemotherapy algorithm |
| Lynn Campbell | Committee member Medical Oncologist | Direct non-financial (non-specific) | Attended an evening meeting sponsored by Roche about immunotherapy on the 3 rd May 2018. General info about immunotherapy drugs in practice. Refreshments provided | May 2018 | May 2018 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Lynn Campbell | Committee member Medical Oncologist | Direct non-financial (non-specific) | Attendance at Oncology Forum meeting, Liverpool, June 2018. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmaceutical | Jun 2018 | Jun 2018 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|-------------------------------|--------------------------------------|---|---|----------|----------|--|---|
| | | | companies, predominantly Novartis, Health care at Home. | | | | |
| Steve Connor From May 2018 | Committee member Neuroradiologist | Direct Financial (non- specific) | Receives payment for work in private hospitals. Paid directly. 95% of private practice fees from HCA insurance. 1/6 of the working week is spent in private practice. Private practice is for general neuroradiology imaging and none in relation to lung cancer. | 2002 | Apr 2018 | | No action other than the process of open declaration |
| Steve Connor From May 2018 | Committee member Neuroradiologist | Non-financial (non- specific) | Research collaborations with head and neck oncology groups, in regards to head and neck cancer treatment. Not related to the scope of this guideline update. | 2012 | Apr 2018 | | No action other than the process of open declaration |
| Sujal Desai | Committee member Radiologist | Direct non-financial (non- specific) | DMC Radiology Reporting Ltd partner. The company does not provide any imaging services. Provides outsourcing teleradiology for the NHS and private sector. No financial remuneration received. | Aug 2005 | Oct 2017 | | No action other than the process of open declaration. The imaging studies cover all body regions and pathologies – there is no specific focus on |

| | | | | | | | |
|-------------|---------------------------------|-------------------------------------|---|----------|----------|--|---|
| | | | | | | | the chest or to any area of the guideline. |
| Sujal Desai | Committee member Radiologist | Direct financial | Taught courses/workshops (not lung cancer), in Hong Kong and Beijing for IDKD. The topics were; interstitial lung diseases, airways diseases and mediastinal and hilar disorders. Flight and accommodation paid, honorarium received. | 2017 | Oct 2017 | | No action other than the process of open declaration IDKD is the course provider therefore payment is non commercial |
| Sujal Desai | Committee member Radiologist | Direct financial (non- specific) | Attended a meeting by Pfizer, for the launch of their antifungal drug Isavuconazole. Paid an honorarium and travel costs. | Nov 2017 | Dec 2017 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Sujal Desai | Committee member Radiologist | Direct non-financial (non-specific) | Speaking at a European Congress of Radiology in Vienna. Conference on smoking related interstitial lung diseases (not lung cancer related), Conference fee waived, travel and accommodation. | Mar 2018 | Feb 2018 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|-------------|---------------------------------|--|--|----------|----------|--|---|
| Sujal Desai | Committee member Radiologist | Direct financial (non- specific) | Run an educational course for Boehringer Ingelheim, on interstitial lung diseases. Honorarium and travel costs will be paid | June 18 | June 18 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Jesme Fox | Committee member Lay member | Direct non-financial professional and personal | Medical Director of Roy Castle Lung Cancer Foundation. The organisation receives grants from pharmaceutical companies as part of its funding. Does not exceed 6% of their income | 1998 | Jul 2017 | | No action other than the process of open declaration |
| Jesme Fox | Committee member Lay member | In direct financial | Presented at a number of conferences and participated in several advisory boards, organised by pharmaceutical companies. Honorarium paid to employer. | 1998 | Jul 2017 | | No action other than the process of open declaration |
| Jesme Fox | Committee member Lay member | In direct financial (non-specific) | Attended an Advisory Board meeting for Takeda. Honorarium paid to employer. Travel and accommodation paid. | Jan 2018 | Jan 2018 | | No action other than the process of open declaration. |

| | | | | | | | |
|-----------|--------------------------------|---|---|----------|----------|--|--|
| | | | Donation given to employer | | | | Not specific to any topic covered in the scope of the guideline. |
| Jesme Fox | Committee member Lay member | Non-financial professional and personal | Paper by O'Dowd was discussed at previous meeting/GCom2. Charity employer, Roy Castle Lung Cancer Foundation funded Dr O'Dowd's 3 year Clinical Research Fellowship post at Nottingham University (2013 to 2015). The research paper discussed was one of several she undertook and published during this time. | 2013 | Feb 2018 | | No action other than the process of open declaration |
| Jesme Fox | Committee member Lay member | Direct non-financial (non-specific) | Participated in a short Advisory Board teleconference 08.04.18, with Boehringer Ingelheim. No honorarium or expenses were paid. The topics discussed were not relevant to Committee discussions (non-medical interventions). | Apr 2018 | Apr 2018 | | |

| | | | | | | | |
|-------------|----------------------------------|---|--|----------|----------|--|---|
| Jesme Fox | Committee member Lay member | Direct non-financial (non-specific) | 31st May, attended a Global Oncology Advocacy Leaders Meeting in Chicago. Travel and accommodation expenses paid by Bristol-Myers Squibb. The topics discussed general cancer issues, not relevant to lung cancer guideline. | May 2018 | Jun 2018 | | No action other than the process of open declaration. Reasonable travel and subsistence. Not specific to any topic covered in the scope of the guideline. |
| Tom Haswell | Committee member Lay member | Direct financial, personal | National Cancer Research Institute (NCRI) – Lung studies group. Attend 2 meetings a year, receives an honorarium. | | Oct 2017 | | No action other than the process of open declaration – non-commercial activity. |
| Tom Haswell | Committee member Lay member | Non-financial professional and personal | Steering Committee member of the British Thoracic Oncology Group. Attended the annual conference where British Thoracic Oncology Group paid travel and accommodation. | 2014 | Feb 2018 | | No action other than the process of open declaration - reasonable travel and subsistence |
| Sue Maughn | Committee member Commissioner | Direct financial | United Kingdom - lung cancer coalition - speaker on sustainability | Apr 2018 | Mar2018 | | No action other than the process of open declaration |

| | | | | | | | |
|---------------|---|-------------------------------------|---|----------|----------|----------|--|
| | | | and transformation partnerships in the commissioning of best practice lung cancer services | | | | reasonable travel and subsistence |
| Andrea McIver | Committee member Nurse | Direct non-financial (non-specific) | Attended the National lung nurse forum for nurses (NLCFN) workshop 14th & 15th May. Accommodation and refreshments provided by NLCFN. | May 2018 | May 2018 | N/A | Direct non-financial (non-specific) Not specific to any topic covered in the scope of the guideline |
| Neal Navani | Committee member Respiratory Physician | Direct financial, personal | Honorarium received for lecture at EBUS masterclass in October 2017. Event hosted by UCLH and sponsored by AstraZeneca. | Oct 2017 | Apr 2017 | Oct 2018 | RQ 1.1 & RQ 1.2 (GComm2) Not involved in making recommendations |
| Neal Navani | Committee member Respiratory Physician | Direct non-financial | Chairing “global advisory board” March 2017, for Astra Zeneca. Travel arranged, no honorarium received. | Mar 2017 | Apr 2017 | Mar 2018 | No action other than the process of open declaration reasonable travel and subsistence |
| Neal Navani | Committee member Respiratory Physician | Direct non-financial | Travel and conference registration from MSD to attend World Lung | Dec 2016 | Apr 2017 | Dec 2017 | No action other than the process of open declaration |

| | | | | | | | |
|-------------|---|---------------------|---|----------------------|----------|--|--|
| | | | Cancer conference Dec 2016 | | | | reasonable travel and subsistence |
| Neal Navani | Committee member Respiratory Physician | Direct financial | Investigator on Lung boost trial (published 2015). Study funded by MRC and included salary payment for 3 years. | 2008 | Oct 2017 | | Paper to be included as evidence for RQ 1.1 & RQ 1.2 (GComm2) Not involved in making recommendations |
| Neal Navani | Committee member Respiratory Physician | Direct financial | Private practice, same scope as NHS work (except, do not prescribe any treatments). Set up as a limited company, income from private practice, is managed via the company. Private income mainly via insurers, on a fee basis. Includes carrying out EBUS procedures (approx 10 per week on the NHS and 1 per week privately) | Apr 2017 for company | Dec 2017 | | RQ 1.1 & RQ 1.2 (GComm2) Not involved in making recommendations Only procedure related to the guideline carried out in private practice is EBUS |
| Neal Navani | Committee member Respiratory Physician | In direct financial | Attended an advisory board (Lung cancer related, but not on any of the topics being covered | | Dec 2017 | | No action other than the process of open declaration |

| | | | | | | | |
|-------------|---|---|--|----------|----------|--|---|
| | | | in the guideline): Honoraria will be paid into the employer's research account. | | | | |
| Neal Navani | Committee member Respiratory Physician | In direct financial | Attended optimising outcomes in lung cancer meeting in Rome, accommodation & travel paid for by AZ. Honorarium paid to research account | Nov 2017 | Dec 2017 | | No action other than the process of open declaration - reasonable travel and subsistence |
| Neal Navani | Committee member Respiratory Physician | In direct financial (non-specific) | Attending in March 2018, EBUS Re-biopsy class Cardiff. Honorarium paid to employer. Astra Zeneca to pay expenses, and travel | Mar 2018 | Dec 2017 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Neal Navani | Committee member Respiratory Physician | Direct financial, personal (non-specific) | Speaking at event in, Slovenia, at the European Society of Thoracic surgery (ESTS), on the cost-effectiveness of lung cancer screening. ESTS paying conference registration fee, expenses and accommodation. | May 2018 | Dec 2017 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|--|--|---|--|----------|----------|----------|--|
| Neal Navani | Committee member Respiratory Physician | Committee member Respiratory Physician | Attended European Endoscopy Forum meeting in Hamburg, accommodation & travel paid for by Olympus. | | Dec 2017 | | No action other than the process of open declaration reasonable travel and subsistence |
| Neal Navani | Committee member Respiratory Physician | Committee member Respiratory Physician | May 2018 Presented at the American Thoracic Society Conference; 'Interventional Pulmonology' in San Diego. Travel and accommodation paid by Oncimmune Ltd. No payment received. | May 2018 | May 2018 | | |
| Marco Scarci Resigned October 2017 | Committee member Thoracic Surgeon | None | N/A | N/A | N/A | N/A | No action |
| Michael Snee Resigned October 2017 | Committee member Clinical Oncologist | Direct non- financial | Attended world lung cancer conference, Vienna – received hospitality from Astra Zeneca (dinner) | Dec 2016 | Mar 2017 | Dec 2017 | No action other than the process of open declaration reasonable travel and subsistence |

| | | | | | | | |
|--|---|----------------------|---|----------|----------|----------|--|
| | | | | | | | Resigned October 2017 |
| Michael Snee Resigned October 2017 | Committee member Clinical Oncologist | Direct financial | Paid work for (Quintiles IMS) clinical research organisation. Involves analysis of anonymous data that has been collected from patients including lung cancer patients with an emphasis on recurrence, toxicity and death. Data collected will be “real world” data from patients not enrolled in clinical trials but undergoing pharmacological treatment with licensed drugs. | | Jul 2017 | | No action |
| David Waller From December 2017 Resigned January 2018 | Committee member Thoracic Surgeon | None | N/A | N/A | N/A | N/A | No action From December 2017 Resigned January 2018 |
| Rhiannon Walters-Davies | Committee member Pharmacist | Direct non-financial | Travel and conference paid by Boehringer, for American Society of | Jun 2017 | Oct 2017 | Jun 2018 | No action other than the process of open declaration |

| | | | | | | | |
|-------------------------|--------------------------------|------------------------------------|--|----------|----------|----------|---|
| | | | Clinical Oncology conference | | | | reasonable travel and subsistence |
| Rhiannon Walters-Davies | Committee member Pharmacist | Direct non-financial | Travel and conference paid by Pierre Fabre, for British Thoracic Oncology Group conference | Jan 2017 | Oct 2017 | Jan 2018 | No action other than the process of open declaration reasonable travel and subsistence |
| Rhiannon Walters-Davies | Committee member Pharmacist | Direct non-financial | Travel and conference paid by Ipsen, for British Oncology Pharmacy Association conference | Oct 2017 | Oct 2017 | | No action other than the process of open declaration reasonable travel and subsistence |
| Rhiannon Walters-Davies | Committee member Pharmacist | In direct financial (non-specific) | 5th Prostate Forum Wales- 11th December, education event sponsored by Astellas. Honorarium paid to pharmacy education endowment fund at Velindre (not the budget holder for the fund). | Dec 2017 | Jan 2018 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|-------------------------|--------------------------------|--|---|----------|----------|--|---|
| Rhiannon Walters-Davies | Committee member Pharmacist | In direct financial (non-specific) | Attended an AZ education event Osimertinib Audit Honorarium paid to education budget where I am not the budget holder. | | Feb 2018 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Rhiannon Walters-Davies | Committee member Pharmacist | In direct financial (non-specific) | Attended a Roche education event, on Pharmacist prescribing immunotherapies Honorarium paid to education budget (not the budget holder). Travel and accommodation paid. | | Feb 2018 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Rhiannon Walters-Davies | Committee member Pharmacist | Direct non-financial personal and professional | Written an article on advances in lung cancer, for pharmacy journal, pending publication | Feb 2018 | Feb 2018 | | No action other than the process of open declaration |
| Rhiannon Walters-Davies | Committee member Pharmacist | Direct non-financial (non-specific) | Attended a meeting on how to horizon forecast for upcoming drugs (all drugs not yet approved). The meeting was held in March 2018 supported by the Association of the | Mar 18 | May 18 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |

| | | | | | | | |
|-------------------------|--------------------------------|-------------------------------------|---|--------|--------|--|---|
| | | | British Pharmaceutical Industry. | | | | |
| Rhiannon Walters-Davies | Committee member Pharmacist | In direct financial (non- specific) | Attend an advisory board, for Astra Zeneca, 5th July 2018, on Durvalumab. Accommodation, travel and accommodation expenses paid. Honorarium paid to education fund. The topics discussed, were not relevant to lung cancer guideline. | Jun 18 | Jul 18 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Rhiannon Walters-Davies | Committee member Pharmacist | In direct financial | Attend an internal meeting (educational) for Boehringer, 26th June 2018, on Afatanib. Honorarium paid to education fund. Accommodation, travel and accommodation expenses paid. | Jun 18 | Jun 18 | | No action other than the process of open declaration. |
| Rhiannon Walters-Davies | Committee member Pharmacist | Direct non-financial (non-specific) | Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by | Jun 18 | Jun 18 | | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline |

| | | | | | | | |
|--------------------|--------------------------------|---------------------------------|--|----------|----------|----------|---|
| | | | the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home. | | | | |
| Nigel Westwood | Committee member Lay member | None | N/A | N/A | N/A | N/A | No action |
| Clifford Wyn Jones | Committee member GP | Direct financial (non-specific) | Assessor for Palliative (paid) Medicine Diploma – Cardiff University | Jan 2017 | Jun 2017 | Apr 2017 | No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. |
| Clifford Wyn Jones | Committee member GP | Direct financial | Framework for Cancer, National GP lead (paid role). An NHS post funded by Macmillan Cancer Support | Jul 2015 | Jun 2017 | | No action other than the process of open declaration Non-commercial |

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.